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Abstract
Backgrounds: Staphylococcus aureus has emerged as a major public health concern because of  the occurrence of  multi-drug 
resistant strains. This study aimed at investigating the multi-drug and vancomycin resistance profile of  S. aureus from different 
infection sites in some teaching hospitals in Nigeria.
Methods: Swabs were collected from different infection sites from out-patients in three teaching hospitals from October 2015 
to May, 2016. The antibiotic-susceptibility test was carried out with selected antibiotics usually administered anti-microbials in 
the treatment of  infections in these hospitals. The prevalence of  multi-drug and vancomycin resistance strains of  S. aureus from 
clinical samples was determined using disk diffusion and agar dilution methods respectively.
Results: The result showed (165)82.5% of  the isolates were resistant to ≥3 antibiotics tested. They were highly resistant to 
ceftazidime 180(90%), cloxacillin 171(85.6%) and augmentin 167(83.3%), but susceptible to ofloxacin 150(75%), gentamicin 
142(71.7%), erythromycin 122(61.1%), ceftriaxone 111(55.6%) and cefuroxime 103(51.7%). All the isolates from the HVS were 
all multidrug resistant strains. While (56)90.16% were multidrug resistant (MDR) in urine samples, followed by (8)88.89% MDR 
strains in sputum, (37)88.81% MDR strains in semen, (49)71.64% MDR strains in wounds and (6)60% MDR strains in ear 
swabs samples. Although (147)73.5% of  the isolates were vancomycin susceptible S. aureus (VSSA), (30)15% were vancomycin 
intermediate resistant S. aureus (VISA) and (89)44.5% of  the isolates were considered vancomycin resistant S. aureus (VRSA).
Conclusions: The high percentage of  the VRSA could have resulted from compromising treatment options and inadequate an-
timicrobial therapy. The implication, infections caused by VRSA would be difficult to treat with vancomycin and other effective 
antibiotics of  clinical importance. Ensuring proper monitoring of  drug administration will, therefore, enhance the legitimate role 
of  vancomycin as an empiric choice for both prophylaxis against and treatment of  staphylococcal infections.
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Introduction
Staphylococcus aureus is frequently found in the human re-
spiratory tract and on the skin.  It is estimated that 20% 
of  the human population are long-term carriers of  S. au-
reus1 whereas it is a transient normal flora of  human skin 
and mucosal surfaces in 20 to 90% of  healthy population. 
To establish its pathogenic potential, S. aureus produces 
toxin and extracellular membrane compounds.4 It pro-
duces various virulence factors including coagulase to 
clot plasma and coats the bacterial cells to probably pre-
vent phagocytosis,5  hyaluronidase and DNAse to break 
down hyaluronic acid and DNA respectively to help in 
its systemic spread6 as well as staphylokinase to dissolve 
fibrin.5 While these virulence factors allow its attachment 
to host’s cells, invade tissues and evade the host’s immune 
system, Silva and Gandra4 indicated that enzymes like co-
agulase and catalase produced by S. aureus are responsible 
for the invasion of  the immune system.
S. aureus infects wounds,7 cause ascending urinary tract 
colonization and infection8 and atopic dermatitis.9 While 
it is responsible for necrotizing pneumonia, skin and soft 
tissue infections, bacteraemia as well as food poisoning 
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through enterotoxin production10-12 and may occur as 
commensals,13 this organism can infect tissues when the 
skin or mucosal barriers have been breached9, to cause 
infections associated with increased burden on health-
care resources14 in community and hospitals15. The un-
restricted use of  antibiotics and inadequate compliance 
to antibiotic regime along with inadequate surveillance 
for anti-microbial resistance are some of  the imperative 
reasons accrued to the emergence of  its highly resistant 
strains.16,17
Since the emergence of  penicillin and methicillin resis-
tant S. aureus strains in 1948 and 1961 respectively18,19 
and virtually all strains of  S. aureus are, today, resistant 
to natural penicillins,aminopenicillins and antipseudomo-
nal-penicillins,20,21 it becomes necessary to find alternative 
antibiotics to treat staphylococcal infections.22 Consequent-
ly, vancomycin, a tricyclic glycopeptide antibiotic, is used 
to treat Gram-positive infections involving methicillin 
resistant S. aureus (MRSA).23,24 This antibiotic interferes 
with bacterial cell wall synthesis, as does penicillin, to 
lyse the cell.25 However, soon after its introduction, re-
duced susceptibility to vancomycin was reported in Japan 
by Hiramatsu.26 This was quickly followed by isolation 
of   vancomycin intermediate resistant S. aureus (VISA) 
and vancomycin resistant S. aureus (VRSA) isolates from 
France,27 United Kingdom,28 Brazil,29 USA,30,31 Germa-
ny,32 India33,34 and Belgium35,36 to confirm that the emer-
gence of  these strains is a global challenge. From patients 
treated with glycopeptides and in patients with suspect-
ed or confirmed MRSA, vancomycin intermediate and a 
few vancomycin-resistant strains have been isolated.37-39 
While Assadullah et al.33 and Khadri and Alzohairy40 in-
dicated that VRSA is not widely seen and a low level of  
resistance to vancomycin is being reported, the knowl-
edge of  the prevalence of  VRSA and their antibiotic sus-
ceptibility pattern becomes fundamental in the selection 
of  appropriate empirical treatment especially in hospital 
settings in the third world countries like Nigeria. This 
study, therefore, aimed at investigating the multi-drug and 
vancomycin resistance profile of  S. aureus from different 
infection sites in some teaching hospitals in Nigeria. This 
is to detect VRSA as potential risk factor that could pose 
challenges to the effectiveness of  anti-microbial therapy 
in the treatment of  staphylococcal infections in developing 
countries like Nigeria.
Materials and methods
Samples were collected from 200 patients attending three 
teaching hospitals in Ogun State, Nigeria. These patients 
were being treated at out-patient Units of  Babcock Uni-
versity Teaching Hospital, Ilisan-Remo, Olabisi Onabanjo 
Teaching Hospital, Sagamu and Federal Medical Center, 
Idi-Aba, Abeokuta, all in Ogun State, Nigeria from Octo-
ber 2015 to May 2016. Patients being treated with system-
ic antibiotics in the last 4 weeks were excluded. The test 
samples collected were taken by carefully rolling swabs 
saturated with sterile peptone water in the different in-
fection sites from different teaching hospitals in Nigeria. 
The swabs were tightly sealed and immediately transport-
ed to the laboratory. The collected infection swab sticks 
were streaked on mannitol salt agar (MSA) and nutrient 
agar which were incubated overnight at 37°C for 24-48 
h.41 The bacterial colonies were subjected to established 
procedures such as Gram staining, microscopic appear-
ance, colony morphology and biochemical tests such as 
tube DNase, catalase and coagulase tests for the charac-
terization of  the strains.42-44
Antibiograms of  the isolates using multi-disc anti-
biotics
Each of  the isolates was standardized using colony sus-
pension method. Each strain's suspension was matched 
with 0.5 McFarland standards to give a resultant concen-
tration of  1.5 × 106 cfu/ml. The antibacterial activity was 
determined using agar diffusion assay technique accord-
ing to the modified Kirby–Bauer diffusion technique43 by 
swabbing the Mueller-Hinton agar (MHA) (Oxoids UK) 
plates with the adjusted overnight culture of  each of  the 
test isolates. Multi-discs (Abtek) containing different anti-
biotics including ofloxacin (5 µg), augmentin (30 µg), cef-
tazioime (30µg), cefuroxine (30 µg), gentamicin (10 µg), 
ceftrioxone (30 µg), erythromycin (5 µg) and cloxacillin (5 
µg) were aseptically placed on the inoculated agar plates 
and incubated at 37°C for 24 h. After 24 h of  incubation, 
the plates were examined for inhibition zones.45 The di-
ameter of  the inhibition zones produced by each antibi-
otic disk was measured to the nearest millimeter, recorded 
and interpreted using the Clinical and Laboratory Stan-
dard Institute Zone Diameter Interpretative Standards.46 
Each bacterial isolate was classified as susceptible (S), in-
termediate (I) and resistant (R) to antibiotics according to 
the zone diameter interpretation standard recommended 
by the Clinical Laboratory Standards Institute.47
Susceptibility of  the isolates to vancomycin
The susceptibility of  the different strains of  S. aureus 
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to vancomycin was further determined by agar dilution 
method using CLSI guidelines.48 Here, gradient plates of  
Mueller Hinton agar were prepared with different concen-
trations, 1 µg/ml, 2 µg/ml, 4 µg/ml, 8 µg/ml and 16 µg/
ml, of  the vancomycin by dissolving vancomycin tablets 
(Mast Diagnostics, Mast Group Ltd., Merseysidem UK, 
Lot: 311380, Exp: 2016 – 06)  in 200 ml of  sterilized mol-
ten agar maintained at a temperature of  50°C. The con-
ical flasks containing the vancomycin tablets were then 
mixed gently till the tablets were completely dissolved. 
The antibiotic-containing agar was then dispensed asep-
tically into Petri dishes labeled according to the various 
concentrations of  the vancomycin prepared and allowed 
to solidify. 0.5 McFarland equivalent inoculums prepared 
using 18 h old culture to give a resultant concentration of  
1.5 × 106 cfu/ml was inoculated by streaking and stab-
bing the concentration gradient vancomycin-containing 
agar plates. The plates were incubated overnight at 35oC 
before being assessed for visible growth. Appearance of  
growth indicated vancomycin resistance.49 Hence, the 
points of  streaking and stabbing that showed bacterial 
growth were referred to as being vancomycin resistant 
while the points that did not show bacterial growth were 
referred to as vancomycin susceptible.
Results
A total number of  200 clinical strains of  S. aureus were 
isolated from wound, urine, semen, ear swabs, sputum 
and high vaginal swabs (HVS) and characterized from dif-
ferent teaching hospitals in Lagos state.  From the sam-
ple distribution, the highest incidence of  S. aureus was 
in wounds 69(34.5%) followed by urine 62(31%), semen 
42(21%), ear swabs 10(5%), sputum 9(4.5%) and HVS 
7(3.5%) as shown in Figure 1.
Figure 1: Percentage distribution of  isolates from different infection sources
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Though these isolates were highly resistant to ceftazi-
dime 180(90%), Cloxacillin 171(85.6%) and augmentin 
167(83.3%), (150)75% of  the isolates were susceptible 
to ofloxacin, followed by gentamicin 143(71.7%), eryth-
romycin 122(61.1%), ceftriaxone 111(55.6%) and ce-
furoxime 103(51.7%) in a descending order. However, 
(165)82.5% of  the isolates exhibited multidrug resistance 
by being resistant to ≥3 of  the test antibiotics as shown 
in Figure 2.
Figure 2: Resistance and Sensitivity profiles of  Staphylococcus aureus to different antibiotics
From the susceptibility of  these isolates to different 
concentrations of  vancomycin used in this study as 
shown in Table 1, (97)48.5% were susceptible to all the 
concentrations of  the vancomycin used while (34)17% 
were resistant to all the concentrations of  the vancomy-
cin used. Considering the number of  strains susceptible 
at each concentration used, (153)76.5%, (149)74.5%, 
(137)68.5%, (123)61.5% and (111)55.5% of  the S. au-
reus isolates were susceptible at 1 µg/ml, 2 µg/ml, 4 µg/
ml, 8 µg/ml and 16 µg/ml respectively. Considering the 
number of  isolates susceptible at concentrations less than 
or equal to each of  the concentration used, (147)73.5%, 
(15)7.5% and (15)7.5% of  the isolates were susceptible 
at concentrations of  ≤2 µg/ml, ≤4 µg/ml and ≤8 µg/
ml respectively but different percentages of  isolates were 
resistant at higher concentrations above the respective 
concentrations at which they were susceptible. Consider-
ing the number of  isolates that were initially resistant to 
vancomycin but later became susceptible to this antibiot-
ic, (2)1% of  the isolates were resistant at 1 µg/ml but sus-
ceptible to other concentrations, (5)2.5% of  the isolates 
were resistant at ≤2 µg/ml but susceptible to all the other 
concentrations and (3)1.5% were resistant at ≤8 µg/ml 
but susceptible only at 16 µg/ml but none of  the isolates 
was resistant at concentration before 4 µg/ml.
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Table 1: The susceptibility of Staphylococcus aureus strains to different concentrations 
of vancomycin antibiotic 
 
Susceptibility of Staphylococcus aureus strains to different concentrations of vancomycin 
antibiotic 
S/N S. aureus Source 1 µg/ml 2 µg/ml 4 µg/ml 8 µg/ml 16 µg/ml 
1.        MDR Wound - - - - - 
2.        MDR Wound + + + + + 
3.        MDR Wound - - + + + 
4.        MDR Wound - - - + + 
5.        SS Wound - - - + + 
21.    MDR Wound - - - + + 
22.    MDR Wound - - - - - 
23.    SS Wound - - - - - 
24.    MDR Wound - - - - - 
25.    MDR Wound - - - - + 
26.    MDR Wound - - - - + 
27.    MDR Wound - - - - - 
         
28.    SS Wound - - - - - 
29.    MDR Wound + + + - - 
30.    SS Wound - - - - - 
31.    MDR Wound - - - - - 
32.    SS Wound - - - - - 
33.    MDR Wound - - - - - 
34.    MDR Wound - - -   51.    MDR Wound + + + + + 
52.    MDR Wound - - - - - 
53.    MDR Wound - - - - + 
54.    SS Wound - - - - - 
55.    MDR Wound + + + + + 
56.    SS Wound - - - - + 
57.    MDR Wound - - + + + 
58.    MDR Wound - - - - - 
72.    MDR Semen - - - - - 
         
73.    SS Semen - - - - - 
74.    MDR Semen + + + + + 
75.    MDR Semen - - + + + 
76.    MDR Semen + + + + + 
77.    MDR Semen + + +   94.    MDR Semen + + + + + 
 
95.    MDR Semen + + + + - 
96.    MDR Semen - - + + + 
97.    MDR Semen + + + + + 
98.    MDR Semen - - - - - 
112.                       MDR Semen - - - - - 
113.                       MDR Urine - - - + + 
114.                       MDR Urine - - - +  130.                       MDR Urine + + + - - 
131.                       MDR Urine - - - - - 
132.                       MDR Urine - - -   151.                       MDR Urine - - - - - 
152.                       SS Urine - - - - - 
153.                       MDR Urine - - - - - 
154.                       MDR Urine - - - + + 
155.                       SS Urine - - - - - 
165.                       SS Urine - - - - - 
166.                       MDR Urine - - - + + 
167.                       MDR Urine - - - -  182.                       SS Sputum - - - - - 
183.                       MDR Sputum - - - - - 
184.                       MDR Ear-swab - - - - - 
193.                       SS Ear-swab - - - - - 
194.                       MDR HVS - - + + + 
195.                       MDR HVS - - - + + 
196.                       MDR HVS - - - - - 
197.                       MDR HVS - - - - - 
198.                       MDR HVS + + + + - 
199.                       MDR HVS - - - - - 
200.                       MDR       
 
95.    MDR Semen + + + + - 
96.    MDR Semen - - + + + 
97.    MDR Semen + + + + + 
98.    MDR Semen - - - - - 
112.                      MDR Semen - - - - - 
113.                      MDR Urine - - - + + 
114.                      MDR Urine - - - +  130.                      MDR Urine + + + - - 
131.                      MDR Urine - - - - - 
132.                      MDR Urine - - -   151.                      MDR Urine - - - - - 
152.                      SS Urine - - - - - 
153.                      MDR Urine - - - - - 
154.                      MDR Urine - - - + + 
155.                      SS Urine - - - - - 
165.                      SS Urine - - - - - 
166.                      MDR Urine - - - + + 
167.                      MDR Urine - - - -  182.                      SS Sputum - - - - - 
183.                      MDR Sputum - - - - - 
184.                      MDR Ear-swab - - - - - 
193.                      SS Ear-swab - - - - - 
194.                      MDR HVS - - + + + 
195.                      MDR HVS - - - + + 
196.                      MDR HVS - - - - - 
197.                      MDR HVS - - - - - 
198.                      MDR HVS + + + + - 
199.                      MDR HVS - - - - - 
200.                      MDR       
 
95.    MDR Semen + + + + - 
96.    MDR Semen - - + + + 
97.    MDR Semen + + + + + 
98.    MDR Semen - - - - - 
112.                       MDR Semen - - - - - 
113.                       MDR Urine - - - + + 
114.                       MDR Urine - - - +  130.                       MDR Urine + + + - - 
131.                       MDR Urine - - - - - 
132.                       MDR Urine - - -   151.                       MDR Urine - - - - - 
152.                       SS Urine - - - - - 
153.                       MDR Urine - - - - - 
154.                       MDR Urine - - - + + 
155.                       SS Urine - - - - - 
165.                       SS Urine - - - - - 
166.                       MDR Urine - - - + + 
167.                       MDR Urine - - - -  182.                       SS Sputum - - - - - 
183.                       MDR Sputum - - - - - 
184.                       MDR Ear-swab - - - - - 
193.                       SS Ear-swab - - - - - 
194.                       MDR HVS - - + + + 
195.                       MDR HVS - - - + + 
196.                       MDR HVS - - - - - 
197.                       MDR HVS - - - - - 
198.                       MDR HVS + + + + - 
199.                       MDR HVS - - - - - 
200.                       MDR       
 
95.    MDR Sem n + + + + - 
96.    MDR Sem n - - + + + 
97.    MDR Sem n + + + + + 
98.    MDR Sem n - - - - - 
112.     MDR Sem n - - - - - 
113.     MDR Urine - - - + + 
114.     MDR Urine - - - +  130.     MDR Urine + + + - - 
131.     MDR Urine - - - - - 
132.     MDR Urine - - -   151.     MDR Urine - - - - - 
152.     SS Urine - - - - - 
153.     MDR Urine - - - - - 
154.     MDR Urine - - - + + 
155.     SS Urine - - - - - 
165.     SS Urine - - - - - 
166.     MDR Urine - - - + + 
167.     MDR Urine - - - -  182.     SS Sputum - - - - - 
183.     MDR Sputum - - - - - 
184.     MDR Ear-swab - - - - - 
193.     SS Ear-swab - - - - - 
194.     MDR HVS - - + + + 
195.     MDR HVS - - - + + 
196.     MDR HVS - - - - - 
197.     MDR HVS - - - - - 
198.     MDR HVS + + + + - 
199.     MDR HVS - - - - - 
200.     MDR       
 
95.    MDR Sem n + + + + - 
96.    MDR Sem n - - + + + 
97.    MDR Sem n + + + + + 
98.    MDR Sem n - - - - - 
112.     MDR Sem n - - - - - 
113.     MDR Urine - - - + + 
114.     MDR Urine - - - +  130.     MDR Urine + + + - - 
131.     MDR Urine - - - - - 
132.     MDR Urine - - -   151.     MDR Urine - - - - - 
152.     SS Urine - - - - - 
153.     MDR Urine - - - - - 
154.     MDR Urine - - - + + 
155.     SS Urine - - - - - 
165.     SS Urine - - - - - 
166.     MDR Urine - - - + + 
167.     MDR Urine - - - -  182.     SS Sputum - - - - - 
183.     MDR Sputum - - - - - 
184.     MDR Ear-swab - - - - - 
193.     SS Ear-swab - - - - - 
194.     MDR HVS - - + + + 
195.     MDR HVS - - - + + 
196.     MDR HVS - - - - - 
197.     MDR HVS - - - - - 
198.     MDR HVS + + + + - 
199.     MDR HVS - - - - - 
200.     MDR       
 
95.  MDR Semen + + + + - 
96.  MDR Semen - - + + + 
97.  MDR Semen + + + + + 
98.  MDR Semen - - - - - 
1 2.  MDR Semen - - - - - 
1 3.  MDR Urine - - - + + 
1 4.  MDR Urine - - - +  130.  MDR Urine + + + - - 
131.  MDR Urine - - - - - 
132.  MDR Urine - - -   151.  MDR Urine - - - - - 
152.  S Urine - - - - - 
153.  MDR Urine - - - - - 
154.  MDR Urine - - - + + 
15 .  S Urine - - - - - 
165.  S Urine - - - - - 
16 .  MDR Urine - - - + + 
167.  MDR Urine - - - -  182.  S Sputum - - - - - 
183.  MDR Sputum - - - - - 
184.  MDR Ear-swab - - - - - 
193.  S Ear-swab - - - - - 
194.  MDR HVS - - + + + 
195.  MDR HVS - - - + + 
196.  MDR HVS - - - - - 
197.  MDR HVS - - - - - 
198.  MDR HVS + + + + - 
19 .  MDR HVS - - - - - 
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According to the Clinical Laboratory Standards Institute 
(CLSI, formerly NCCLS), S. aureus isolates for which 
vancomycin MIC are 4-8 μg/ml are classified as vanco-
mycin-intermediate (VISA), and isolates for which van-
comycin MIC´s are greater than 8 μg/ml are classified 
as vancomycin-resistant.50 From case definition of  Kluy-
tmans et al.51 indicating vancomycin MIC of  ≤2 µg/ml 
as vancomycin-susceptible S. aureus (VSSA), vancomycin 
MIC = 4-8 µg/ml as vancomycin-intermediate suscepti-
ble S. aureus (VISA) and vancomycin MIC ≥ 16 µg/ml 
as vancomycin-resistant S. aureus (VRSA), (147)73.5% 
of  the isolates were vancomycin susceptible S. aureus 
(VSSA). Combining those isolates susceptible at concen-
trations ≤4 µg/ml and those of  susceptible at ≤8 µg/ml, 
(30)15% of  the isolates were considered vancomycin in-
termediate resistant S. aureus (VISA). However, (34)17% 
of  the isolates that were resistant to all the concentra-
tions of  the vancomycin used were considered VRSA in 
addition to (55)27.5% of  the isolates that were resistant 
to vancomycin at the concentration of  16 µg/ml. Hence, 
(89)44.5% of  the isolates were considered VRSA. Con-
sidering the distribution of  S. aureus on the basis of  their 
susceptibility to vancomycin with respect to isolates from 
the different sampling sources, (180)90% of  the S. aureus 
from ear samples were susceptible to vancomycin while 
(20)10% of  the isolates were vancomycin intermediate 
resistant S. aureus (VISA) and no vancomycin resistant S. 
aureus. In HVS, VSSA was (4)57.14%, VISA was (2)28.5% 
and VRSA was (1)14.3%. 
In semen samples, VSSA was (22)53.5%, VISA was 
(3)7% and VRSA was (17)39.5%. In sputum samples, 
VSSA was (6)66.7%, VISA was (1)11.1% and VRSA 
was (2)22.2%. While VSSA was (18)29.0%, VISA was 
(6)9.7% and VRSA was (38)61.29% in urine samples, 
wound samples had VSSA 43(61.8%), VISA 6(8.8%) and 
VRSA 20(29.4%). Invariably, the percentages of  VRSA 
in the various samples collected varied in a descending 
order from urine samples having VRSA 38(61.29%), fol-
lowed by semen 17(39.5%) > wound 20(29.4%) > spu-
tum 2(22.2%) > HVS 1(14.3%) > ear swabs 0(0%). While 
the isolates from the HVS were all multi-drug resistant 
strains, (59)90.2% of  isolates from the urine samples 
were multi-drug resistant, followed by (8)88.9% MDR 
strains from sputum, (37)88.81% MDR strains from se-
men, (49)71.64% MDR strains from wounds and (6)60% 
MDR strains from ear swabs as shown in Figure 3.
Figure 3: Percentage distribution of  multi-drug and vancomycin susceptibility of  S. aureus in each infection samples
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Discussion
Staphylococcus aureus has been one of  the most problem-
atic nosocomial pathogens and a major threat to human 
health worldwide due to its anti-microbial resistance, in-
fectivity and possession of  virulence factors52,53 as well as 
its ability to repeatedly acquire resistance to overcome the 
challenges presented by the new anti-staphylococcal antibi-
otics.54 Although vancomycin is the main antimicrobial 
agent available to treat serious staphylococcal infections, es-
pecially those of  MRSA, a decrease in vancomycin sus-
ceptibility of  S. aureus and isolation of  vancomycin inter-
mediate and resistant S. aureus from many countries have 
been reported.55-57 Since its first being reported in 1997, 
the threat of  vancomycin resistance in S. aureus has been 
the topic of  intensive research, discussion and cause for 
alarm in the health care community.58 There is widespread 
concern that vancomycin-resistant S. aureus poses, by far, 
the greatest risk to patients, given the virulence of  the 
organism.
In this study, the prevalence of  VRSA was found to be 
(89)44.5% of  the investigated S. aureus isolated. However, 
the (89)44.5 % vancomycin resistance rate of  S. aureus, 
in this study, was higher than that of  21%  reported by 
Flamm et al.59 in Nepal, 3.6% reported in Iran,60 40% re-
ported by Mimejad et al.61 in Iran and the 16.4% reported 
by Godebo et al.62 in Ethiopia. Although these variations 
in the degree of  resistance are geographically based, these 
varied degrees of  resistance to vancomycin have resulted 
in an increasing concern about its therapeutic effective-
ness in serious staphylococcal infections. While the deter-
mination of  the antimicrobial susceptibility is crucial for 
an optimal therapy, for epidemiological purposes and for 
infection control measures,60,63 the treatment of  the S. au-
reus infections has become problematic because of  the 
emergence of  resistance to methicillin, vancomycin and 
other antibiotics.60,64
In agreement with De Lassence et al.65 who indicated 
that VRSA tend to be multi-drug resistant against a large 
number of  currently available anti-microbial agents, com-
promise treatment options and increase the likelihood 
of  inadequate anti-microbial therapy and a resultant in-
crease in morbidity and mortality, VRSA, a trait assigned 
to S. aureus strains with vancomycin minimum inhibito-
ry concentration greater than 8 µg/ml,66,67 showed high 
percentages of  resistance to a wide range of  anti-micro-
bial agents including augmentin 167(83.3%), cloxacillin 
171(85.6%) and ceftazidime 180(90%). Consequently, 
treatment of  Staphylococcus infections will become more 
difficult because (165)82.5% of  the strains, in this study, 
were resistant to ≥3 antibiotics tested at the same time.68 
As the frequency of  antibiotic-resistant bacteria among 
countries is proportional to their relative rates of  antibi-
otic use,69,70 a never-ending need to produce and market 
costlier new antibiotics to treat progressively more resis-
tant infections is inevitable.71
As the case may be in Nigeria and some other developing 
countries, virtually all drugs are sold in drug stores called 
“Chemists” in the local parlance without obtaining anti-
biotic sensitivity test results from the medical laboratories 
or prescriptions from clinicians. These factors, according 
to Yah et al.72, increase the rate of  drug abuse and con-
sequently increase the rate of  development of  bacterial 
resistance to antibiotics in a geometric rate higher than 
that in developed countries. In this study, the presence 
of  VISA may be an important indicator of  the insidious 
decline of  the clinical effectiveness of  vancomycin in the 
hospitals or injudicious use of  vancomycin in hospitals 
for wrongly diagnosed or false positive MRSA. While 
(34)17% of  the isolates were resistant to MIC ≥16 µg/
ml of  the vancomycin antibiotic showed a fast increas-
ing rate of  development of  vancomycin resistant S. au-
reus especially among clinical isolates, having (89)44.5% 
VRSA is an indication that S. aureus has become more 
resistant to vancomycin in comparison to other reports. 
This may, probably, pose a big problem towards its use 
as the ultimate drug against MRSA. These isolates may 
have acquired resistance by mutation and thickening of  
cell wall due to accumulation of  excess amounts of  pep-
tidoglycan.73,74 The cell wall thickening may have caused 
vancomycin molecules to become trapped in the outer 
layers of  the cell wall, clog the peptidoglycan meshwork 
and form physical barriers limiting its access to the cyto-
plasmic membrane where the functional targets of  van-
comycin are located.75
In this study, that the percentages of  VRSA varied in 
a descending order from urine samples having VRSA 
38(61.26%), followed by semen 17(39.5%) > wound 
20(29.4%) > sputum 2(22.22%) > HVS 1(14.29%) > 
ears (0%) is contrary to the report of  Dhand et al.76 who 
found no VRSA, VISA and VSSA in 250 S. aureus from 
clinical samples. On the other hand, while VRSA (4.7%), 
VISA (9.3%) and VSSA (86.0%) were reported by Ilang 
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et al.77, 26.7% of  VRSA in post-operative pus samples78 
and 36.1% of  VISA in blood and body fluids79 were re-
ported. These differences might be due to prolonged an-
tibiotic treatment of  severely sick patients, who generally 
have longer hospital stays, resulting in enhanced selection 
pressure. Therefore, prolonged use of  antibiotics and 
prolonged hospitalization are other important factors 
making hospitals an ideal place for transmission and per-
petuation of  VRSA.80
In conclusion, this study shows that there is a high preva-
lence of  vancomycin-resistant S. aureus (VRSA) amongst 
isolates from the clinical samples investigated. The VRSA 
were multi-drug resistant against a large number of  cur-
rently available anti-microbial agents. The high percent-
age of  the VRSA could have resulted from compro-
mising treatment options and inadequate anti-microbial 
therapy, a lack of  sufficient knowledge on the danger of  
the wrong use of  antibiotics, high proximity to a large 
number of  unlicensed drug vendors and the inappro-
priate use of  broad spectrum antibiotics in the medical 
practice. Efforts should, therefore, be made in ensuring 
proper monitoring of  drug administration and its use to 
prevent drug misuse and abuse as well as to prevent or re-
duce the rate of  anti-microbial resistance amongst clinical 
pathogens. These will, therefore, enhance the legitimate 
role of  vancomycin as an empiric choice for both pro-
phylaxis against and treatment of staphylococcal infections.
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